Christopher Weber to Inflammatory Bowel Diseases
This is a "connection" page, showing publications Christopher Weber has written about Inflammatory Bowel Diseases.
Connection Strength
1.344
-
Histopathologic Evaluation and Single-cell Spatial Transcriptomics of the Colon Reveal Cellular and Molecular Abnormalities Linked to J-Pouch Failure in Patients With Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol. 2025; 19(10):101563.
Score: 0.545
-
Inflammatory bowel disease: is it really just another break in the wall? Gut. 2007 Jan; 56(1):6-8.
Score: 0.151
-
Colonic Tissue Expression of MAdCAM-1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease. Clin Transl Sci. 2025 12; 18(12):e70422.
Score: 0.141
-
Potential Dietary and Therapeutic Strategies Involving Indole-3-Carbinole in Preclinical Models of Intestinal Inflammation. Nutrients. 2023 Nov 30; 15(23).
Score: 0.122
-
Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med. 2023 06; 29(6):1520-1529.
Score: 0.118
-
Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
Score: 0.089
-
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
Score: 0.083
-
Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem. 2010 Apr 16; 285(16):12037-46.
Score: 0.047
-
T cell protein tyrosine phosphatase protects intestinal barrier function by restricting epithelial tight junction remodeling. J Clin Invest. 2021 09 01; 131(17).
Score: 0.026
-
The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. Mucosal Immunol. 2018 09; 11(5):1454-1465.
Score: 0.021